New Sleeping Pill Suvorexant, Different Mechanism of action than Benzos/Z Drugs

By Jake. · Jul 31, 2015 ·
  1. Jake.
    Suvorexant (trade name Belsomra) is a selective, dual receptor antagonist marketed by Merck & Co. for the treatment of insomnia.
    It is effective for placebo.

    Suvorexant was approved for sale by the U.S. Food and Drug Administration (FDA) on August 13, 2014.

    The U.S. Drug Enforcement Agency (DEA) has placed it on the list of schedule IV controlled substances. The drug became available in Japan in November 2014 and in the United States in February 2015.

    For UK and EU users, I have checked on the NHS new drugs register and it is currently in stage 3 clinical trials.

    Looking at the side effect profile, it doesn't look much different from the Z drugs, with the same notorious zombie effects. People driving or eating a litre of ice cream or painting their front door and then waking up wondering what has happened.

    It is interesting that it targets the Orexin A and B chemicals rather than the Z drugs and Benzos which target GABAa receptors, albeit via a different mechanism.

    As this is such a new drug, we won't see addiction and habituation yet, but personally I wouldn't take it. No doubt it will be touted as the best thing since sliced bread by Merck, it is stated as having a low potential for addiction, having a half life of 12.2 hours.

    It has also been proven to alter driving reactions the following morning so somewhat worrying unless you have a good 12 hours to commit to sleep.

    Has anyone any Pharmacological experience with Orexin antagonists?

    There is little information than from the clinical trials and risk registers at the moment,

    This one does seemed to have been rushed through FDA approval!

    Do not use SWIM!
    "Please give Rep, Donate and let us Further the Betterment of Drugs Forum"

    "Take a look at the wrong man beating up the wrong guy, I wonder if he'll ever know, he's in the best selling show, is there life on Mars....."

    Share This Article


To make a comment simply sign up and become a member!